Antitumor vaccination: where we stand.

scientific article

Antitumor vaccination: where we stand. is …
instance of (P31):
review articleQ7318358
scholarly articleQ13442814

External links are
P698PubMed publication ID11074658

P2093author name stringBronte V
Forni G
Tura S
Zanon P
Bocchia M
Colombo MP
Lemoli RM
Di Nicola M
Rondelli D
Massaia M
De Vincentiis A
Lanata L
P433issue11
P304page(s)1172-1206
P577publication date2000-11-01
P1433published inHaematologicaQ5638209
P1476titleAntitumor vaccination: where we stand
P478volume85

Reverse relations

cites work (P2860)
Q37428422A novel non-Hodgkin lymphoma murine model closer to the standard clinical scenario
Q33517133Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model
Q34859794Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge.
Q59796509Co-expression of IL-15 enhances anti-neuroblastoma effectivity of a tyrosine hydroxylase-directed DNA vaccination in mice
Q81846523Comparison of protective effect of protein and DNA vaccines hsp90 in murine model of systemic candidiasis
Q34110774Early expression of stem cell-associated genes within the CD8 compartment after treatment with a tumor vaccine
Q47965988Gene cloning of murine alpha-fetoprotein gene and construction of its eukaryotic expression vector and expression in CHO cells
Q36907752Identification of HLA-A24-restricted CD8(+) cytotoxic T-cell epitopes derived from mammaglobin-A, a human breast cancer-associated antigen
Q45160017Identification of inhibitors of myeloid-derived suppressor cells activity through phenotypic chemical screening
Q51012673Interleukin-15 enhances T-cell responses by stimulation with dendritic cells.
Q40516283Poly (I:C) enhances the anti-tumor activity of canine parvovirus NS1 protein by inducing a potent anti-tumor immune response.
Q49395392Salmonella Immunotherapy Improves the Outcome of CHOP Chemotherapy in Non-Hodgkin Lymphoma-Bearing Mice.
Q36421292Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
Q36171935Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro
Q35007586Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo
Q30915166The efficacy of adjuvant immunochemotherapy with OK-432 after curative resection of gastric cancer: an individual patient data meta-analysis of randomized controlled trials
Q36694952Transduction of dendritic cells with recombinant adenovirus encoding HCA661 activates autologous cytotoxic T lymphocytes to target hepatoma cells
Q38269469Viral genes as oncolytic agents for cancer therapy

Search more.